Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Published studies have reported plasma GHK-Cu levels of approximately 200 ng/mL at age 20, declining to approximately 80 ng/mL by age 60
REDEFINE 2 Trial Type 2 Diabetes with Obesity The companion REDEFINE 2 trial, also published in 2025, enrolled 1,206 adults with type 2 diabetes and obesity or overweight, demonstrating the combinations efficacy in this more metabolically compromised population: Mean weight loss of 13.7% compared to 3.4% with placebo over 68 weeks 73.5% achieved hemoglobin A1c of 6.5% or less compared to 15.9% with placebo Greater proportions reaching multiple weight thresholds including 5%, 10%, 15%, and 20% reduction Significant glycemic improvement with mean A1c reduction demonstrating disease modification potential Favorable metabolic profile changes including improvements in blood pressure and lipids These findings established that the combination maintains substantial efficacy even in patients with the metabolic dysfunction of established type 2 diabetes, a population often showing reduced response to weight-loss interventions
Bayik, D
MT-II acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R, MC5R), with its most extensively studied effect being the stimulation of melanogenesis the biological process by which melanin pigment is produced in skin and hair follicles
